Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guna-Interleukin 10
- Development stage
- Unknown
- Lead developer
- Guna
- Modality
- Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Guna-Interleukin 10 is a low-dose homeopathic medicinal product developed by GUNA S.p.A. utilizing proprietary Sequential Kinetic Activation (SKA) technology. It contains Interleukin-10 (IL-10) at a 4C dilution, resulting in concentrations in the picogram to femtogram range. The product is designed to modulate the immune system by supplementing anti-inflammatory cytokine signaling, thereby reducing chronic inflammation. It is primarily used for the management of chronic pain and inflammatory conditions such as rheumatoid arthritis, fibromyalgia, and osteoporosis. In clinical settings, it has been evaluated for its ability to maintain remission or low disease activity in early rheumatoid arthritis, often in combination with other low-dose cytokines like IL-4 and anti-IL-1.
- Brand names
- Guna-Interleukin 10Guna-Interleukin10Guna-Interleukin-10
- Other names
- GUNA-IL10GUNA-IL-10GUNA-IL 10low-dose SKA Interleukin-10
02
Targets
IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on Guna-Interleukin 10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guna-Interleukin 10.